Neonatal Medicine

  • 제18권2호
  • /
  • Pages.234-239
  • /
  • 2011
  • /
  • 2287-9412(pISSN)
  • /
  • 2287-9803(eISSN)
대한신생아학회 (The Korean Society of Neonatology)
권호 표지
DOI QR코드

DOI QR Code

1,250 g 미만 미숙아에서 예방적 Ibuprofen의 효과

Effect of Prophylactic Ibuprofen in Preterm Infants Less than 1,250 g in Birth Weight

  • 여문수 (한양대학교 의과대학 소아청소년과학교실) ;
  • 최경빈 (한양대학교 의과대학 소아청소년과학교실) ;
  • 이현주 (한양대학교 의과대학 소아청소년과학교실) ;
  • 박현경 (한양대학교 의과대학 소아청소년과학교실) ;
  • 김창렬 (한양대학교 의과대학 소아청소년과학교실) ;
  • 설인준 (한양대학교 의과대학 소아청소년과학교실)
  • Yeo, Mun-Soo (Department of Pediatrics, College of Medicine, Hanyang University) ;
  • Choi, Kyung-Vin (Department of Pediatrics, College of Medicine, Hanyang University) ;
  • Lee, Hyun-Ju (Department of Pediatrics, College of Medicine, Hanyang University) ;
  • Park, Hyun-Kyung (Department of Pediatrics, College of Medicine, Hanyang University) ;
  • Kim, Chang-Ryul (Department of Pediatrics, College of Medicine, Hanyang University) ;
  • Seol, In-Joon (Department of Pediatrics, College of Medicine, Hanyang University)
  • 발행 : 2011.11.30
⟨ 이전 논문 다음 논문 ⟩

초록

목적: 최근 indomethacin의 대체약으로 ibuprofen이 미숙아 동맥관 개존증의 예방과 치료에 사용되고 있다. 본 연구는 1,250g 미만의 미숙아를 대상으로 ibuprofen의 예방적 치료 효과 및 임상 경과를 분석하고자 하였다. 방법: 2009년 11월부터 2010년 7월까지 본원 신생아 중환자실에 입원한 1,250 g 미만의 동맥관 개존증 환아 39명을 대상으로 후향적으로 의무기록을 조사하였다. Ibuprofen의 예방적 투여군(출생 후 24시간 이내에 ibuprofen 투여) 13명에 대해 재태연령과 출생체중을 과거 대응(historical match)하여 대조군 26명으로 분류하였고, 두 군의 동맥관 개존증 빈도, 임상 경과 및 합병증을 분석하였다. 결과: Ibuprofen을 투여한 예방적 투여군과 대조군 간의 동맥관 폐쇄율(69.2% vs 77.7%, P=0.825)은 유의한 차이가 없었고, ibuprofen 치료에 실패하여 동맥관 결찰술을 시행 받은 경우도 두 군간에 유의한 차이가 없었다(23.1% vs 30.8%, P=0.719). 약물과 관련된 부작용으로 위장관 천공이 발생한 경우는 예방적 투여군에서 더 많은 경향을 보였으나 대상수의 부족 등으로 통계적 유의성은 없었다(30.8% vs 11.5%, P=0.194). 뇌실 내 출혈(grade${\geq}$3) 및 다른 미숙아 합병증의 발생률도 두 군간 차이는 없었다. 결론: 미숙아에서 ibuprofen의 예방적인 투여가 동맥관 폐쇄율, 동맥관 결찰술 그리고 고도의 뇌실 내 출혈의 빈도를 감소시키지 못하였다. 향후 예방적 ibuprofen 사용과 관련하여 효과 및 부작용에 대한 더 많은 연구가 되어야 할 것이다.

Purpose: Ibuprofen is used for prevention and treatment of patent ductus arteriosus as an alternative drug of indomethacin in very premature infants. We aimed to determine the effect of prophylactic ibuprofen on patent ductus arteriosus and clinical outcomes in preterm infants less than 1,250 g. Methods: A retrospective review of 39 preterm infants who were admitted to our neonatal intensive care unit from November 2009 to July 2010 was performed. Patients were divided into a prophylactic group (n=13) and a matched historical control group (n=26), where prophylactic ibuprofen were administrated within 24 hours after birth. The rate of ductal closure, side-effects of drug treatment and clinical outcomes were compared between two groups. Results: Comparison of the prophylactic and control groups revealed no significant differences in the rate of ductal closure (69.2% vs 77.7%, P=0.825) and surgical ligation (23.1% vs 30.8%, P=0.719). Occurrence of bowel perforation was more frequent in the prophylactic group than the control group, but was not significant (30.8% vs 11.5%, P=0.194). The frequency of intraventricular hemorrhage (grade${\geq}$3) and other outcomes did not differ between the groups. Conclusion: Ibuprofen prophylaxis in preterm infants did not decrease the rate of ductal closure, the need for surgical ligation and the incidence of intraventricular hemorrhage. Further studies are needed to investigate the beneficial effect and associated adverse events attributed to ibuprofen prophylaxis.

키워드

참고문헌

  1. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2010;(4):CD003481.
  2. Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards AD. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000;47:36-42. https://doi.org/10.1203/00006450-200001000-00009
  3. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999;135:733-8. https://doi.org/10.1016/S0022-3476(99)70093-4
  4. Romagnoli C, De Carolis MP, Papacci P, Polimeni V, Luciano R, Piersigilli F,et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 2000;67:676-83. https://doi.org/10.1067/mcp.2000.107048
  5. Van Overmeire B, Smets K, Lecoutere D, Van de Broek H, Weyler J, Degroote K, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000;343:674-81. https://doi.org/10.1056/NEJM200009073431001
  6. Ohlsson A, Shah SS. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2011;(7):CD004213.
  7. Van Overmeire B, Allegaert K, Casaer A, Debauche C, Decaluwe W, Jespers A, et al. Prophylactic ibuprofen in premature infants: A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1945-9. https://doi.org/10.1016/S0140-6736(04)17477-1
  8. Richards J, Johnson A, Fox G, Campbell M. A second course of ibuprofen is effective in the closure of a clinically significant PDA in ELBW infants. Pediatrics 2009;124:e287-93. https://doi.org/10.1542/peds.2008-2232
  9. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage : a study of infants with birth weights less than 1,500 gm. J Pediatri 1978;92:529-34. https://doi.org/10.1016/S0022-3476(78)80282-0
  10. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001;163:1723-9. https://doi.org/10.1164/ajrccm.163.7.2011060
  11. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179-201.
  12. An international classification of retinopathy of prematurity. Pediatrics 1984;74:127-33.
  13. Fujii AM, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol 2002;22:535-40. https://doi.org/10.1038/sj.jp.7210795
  14. Knight DB. The treatment of patent ductus arteriosus in preterm infants. A review and overview of randomized trials. Semin Neonatol 2001;6:63-73. https://doi.org/10.1053/siny.2000.0036
  15. Ment LR, Oh W, Ehrenkranz RA, Phillip AG, Vohr B, Allan W, et al. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. J Pediatr 1994;124:951- 5. https://doi.org/10.1016/S0022-3476(05)83191-9
  16. Clyman RI, Chorne N. Patent ductus arteriosus: evidence for and against treatment. J Pediatr 2007;150:216-9. https://doi.org/10.1016/j.jpeds.2006.12.048
  17. Bancalari E, Claure N, Gonzalez A. Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 2005;88: 192- 201. https://doi.org/10.1159/000087582
  18. Clyman RI, Mauray F, Roman C, Heymann MA, Payne B. Effect of gestational age on ductus arteriosus response to circulating prostaglandin E2. J Pediatr 1983;102:907-11. https://doi.org/10.1016/S0022-3476(83)80023-7
  19. Schmidt B, Davis P, Moddemann D, Ohlsson A, Roberts RS, Saigal S, et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med 2001;344:1966-72. https://doi.org/10.1056/NEJM200106283442602
  20. Narayanan M, Cooper B, Weiss H, Clyman RI. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000;136:330-7 https://doi.org/10.1067/mpd.2000.103414
  21. Lee HS, Choi WS, Choi BM, Lee KH, Eun BL, Yoo KH, et al. Usefulness of B-type natriuretic peptide assay in predicting symptomatic patent ductus arteriosus in preterm infants. J Korean Soc Neonatol 2004;11:44-53.
  22. Kim SM. Therapeutic strategics for PDA in prematurity (How to treat PDA? When to treat PDA?). J Korean Soc Neonatol 2007;14: 142-52.
  23. Dani C, Bertini G, Reali MF, Murru P, Fabris C, Vangi V, et al. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants. Acta Paediatr 2000;89:1369-74. https://doi.org/10.1111/j.1651-2227.2000.tb00767.x
  24. Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet 2004;364:1939-44. https://doi.org/10.1016/S0140-6736(04)17476-X
  25. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics 2006;117: 1113-21. https://doi.org/10.1542/peds.2005-1528
  26. Sangtawesin V, Sangtawesin C, Raksasinborisut C, Sathirakul K, Kanjanapattanakul W, Khorana M, et al. Oral ibuprofen prophylaxis for symptomatic patent ductus arteriosus of prematurity. J Med Assoc Thai 2006;89:314-21.
  27. Waleh N, McCurnin DC, Yoder BA, Shaul PW, Clyman RI. Patent ductus arteriosus ligation alters pulmonary gene expression in preterm baboons. Pediatr Res 2011;69:212-6. https://doi.org/10.1203/PDR.0b013e3182084f8d
  28. Choi W, Shin JY, Choi BM, Yoo KH, Eun BL, Hong YS, et al. The effects of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants. Korea J Pediatr 2006;49:1315-23. https://doi.org/10.3345/kjp.2006.49.12.1315
  29. Lee SJ, Kim JY, Park EA, Sohn SS. The pharmacological treatment of patent ductus arteriosus in premature infants with respiratory distress syndrome: oral ibuprofen vs. indomethacin. Korea J Pediatr 2008.